EarningsNxt
CalendarInsightsFor AgentsAbout
EarningsNxt

Earnings briefings in plain English, before and after the bell. Free calendar, Pro briefs at $8/mo.

Get briefs in your inbox For agents

Popular tickers

AAPLMSFTGOOGLAMZNNVDAMETATSLAJPMVUNHJNJWMT

Product

  • Earnings Calendar
  • Pricing
  • For Agents

Resources

  • Insights
  • API Reference
  • FAQ
  • llms.txt

Company

  • About
  • Contact
  • X / Twitter
  • StockTwits
  • Instagram

© 2026 EarningsNxt. For informational purposes only. Not financial advice. AI-assisted content may contain errors.

Terms of ServicePrivacy PolicyDisclaimerDisclosureAccessibilityDo Not Sell My Info
  1. Home
  2. NVS

Equity Profile

NVS

Novartis AG

Health CarePharmaceuticals$272.0B market cap

Earnings scorecard

Last 63Q

EPS beat streak

1Q

EPS beat rate

59%

Avg EPS surprise

+4.74%

Avg 1-day reaction

+0.05%

Earnings history

64 quarters
Full history
QuarterReportedEst.ActualSurprise1-day
Q3-2026UpcomingOct 27, 2026————Preview
Q2-2026Jul 21, 2026$2.19$2.41+9.79%+2.88%Preview
Q1-2026Apr 28, 2026$2.07$1.99-5.60%+0.91%Preview
Q4-2025Feb 4, 2026$1.99$2.03+2.11%+2.04%Preview
Q3-2025Oct 28, 2025$2.26$2.25-0.57%-4.42%Preview
Q2-2025Jul 17, 2025ProPreview
Q1-2025Apr 29, 2025ProPreview
Q4-2024Jan 31, 2025ProPreview
Q3-2024Oct 29, 2024ProPreview
Q2-2024Jul 18, 2024ProPreview
Q1-2024Apr 23, 2024ProPreview
Q4-2023Jan 31, 2024ProPreview
Q3-2023Oct 24, 2023ProPreview
Q2-2023Jul 18, 2023ProPreview
Q1-2023Apr 25, 2023ProPreview
Q4-2022Feb 1, 2023ProPreview
Q3-2022Oct 25, 2022ProPreview
Q2-2022Jul 19, 2022ProPreview
Q1-2022Apr 26, 2022ProPreview
Q4-2021Feb 2, 2022ProPreview
Q3-2021Oct 26, 2021ProPreview
Q2-2021Jul 21, 2021ProPreview
Q1-2021Apr 27, 2021ProPreview
Q4-2020Jan 26, 2021ProPreview
Q3-2020Oct 27, 2020ProPreview
Q2-2020Jul 21, 2020ProPreview
Q1-2020Apr 28, 2020ProPreview
Q4-2019Jan 29, 2020ProPreview
Q3-2019Oct 22, 2019ProPreview
Q2-2019Jul 18, 2019ProPreview
Q1-2019Apr 24, 2019ProPreview
Q4-2018Jan 30, 2019ProPreview
Q3-2018Oct 18, 2018ProPreview
Q2-2018Jul 18, 2018ProPreview
Q1-2018Apr 19, 2018ProPreview
Q4-2017Jan 24, 2018ProPreview
Q3-2017Oct 24, 2017ProPreview
Q2-2017Jul 18, 2017ProPreview
Q1-2017Apr 25, 2017ProPreview
Q4-2016Jan 25, 2017ProPreview
Q3-2016Oct 25, 2016ProPreview
Q2-2016Jul 19, 2016ProPreview
Q1-2016Apr 21, 2016ProPreview
Q4-2015Jan 27, 2016ProPreview
Q3-2015Oct 27, 2015ProPreview
Q2-2015Jul 21, 2015ProPreview
Q1-2015Apr 23, 2015ProPreview
Q4-2014Jan 27, 2015ProPreview
Q3-2014Oct 28, 2014ProPreview
Q2-2012Jul 19, 2012ProPreview
Q1-2011Apr 19, 2011ProPreview
Q4-2010Jan 27, 2011ProPreview
Q3-2010Oct 21, 2010ProPreview
Q2-2010Jul 15, 2010ProPreview
Q1-2010Apr 20, 2010ProPreview
Q4-2009Jan 26, 2010ProPreview
Q3-2009Oct 22, 2009ProPreview
Q2-2009Jul 16, 2009ProPreview
Q1-2009Apr 23, 2009ProPreview
Q4-2008Jan 28, 2009ProPreview
Q3-2008Oct 20, 2008ProPreview
Q2-2008Jul 17, 2008ProPreview
Q1-2008Apr 21, 2008ProPreview
Q4-2007Jan 17, 2008ProPreview

Next report

Q3-2026

Tue, Oct 27

Before the open

Est. EPS

—

Est. Rev

—

Read the preview

About NVS

Sector
Health Care
Industry
Pharmaceuticals
Market cap
$272.0B

59 earlier quarters of EPS results and stock reactions are part of Pro.

No charge today · $8/mo after 7 days · Cancel anytime

Q2-2025Jul 17, 2025ProPreview
Q1-2025Apr 29, 2025ProPreview
Q4-2024Jan 31, 2025Pro
Preview
Q3-2024Oct 29, 2024ProPreview
Q2-2024Jul 18, 2024ProPreview
Q1-2024Apr 23, 2024ProPreview
Q4-2023Jan 31, 2024ProPreview
Q3-2023Oct 24, 2023ProPreview
Q2-2023Jul 18, 2023ProPreview
Q1-2023Apr 25, 2023ProPreview
Q4-2022Feb 1, 2023ProPreview
Q3-2022Oct 25, 2022ProPreview
Q2-2022Jul 19, 2022ProPreview
Q1-2022Apr 26, 2022ProPreview
Q4-2021Feb 2, 2022ProPreview
Q3-2021Oct 26, 2021ProPreview
Q2-2021Jul 21, 2021ProPreview
Q1-2021Apr 27, 2021ProPreview
Q4-2020Jan 26, 2021ProPreview
Q3-2020Oct 27, 2020ProPreview
Q2-2020Jul 21, 2020ProPreview
Q1-2020Apr 28, 2020ProPreview
Q4-2019Jan 29, 2020ProPreview
Q3-2019Oct 22, 2019ProPreview
Q2-2019Jul 18, 2019ProPreview
Q1-2019Apr 24, 2019ProPreview
Q4-2018Jan 30, 2019ProPreview
Q3-2018Oct 18, 2018ProPreview
Q2-2018Jul 18, 2018ProPreview
Q1-2018Apr 19, 2018ProPreview
Q4-2017Jan 24, 2018ProPreview
Q3-2017Oct 24, 2017ProPreview
Q2-2017Jul 18, 2017ProPreview
Q1-2017Apr 25, 2017ProPreview
Q4-2016Jan 25, 2017ProPreview
Q3-2016Oct 25, 2016ProPreview
Q2-2016Jul 19, 2016ProPreview
Q1-2016Apr 21, 2016ProPreview
Q4-2015Jan 27, 2016ProPreview
Q3-2015Oct 27, 2015ProPreview
Q2-2015Jul 21, 2015ProPreview
Q1-2015Apr 23, 2015ProPreview
Q4-2014Jan 27, 2015ProPreview
Q3-2014Oct 28, 2014ProPreview
Q2-2012Jul 19, 2012ProPreview
Q1-2011Apr 19, 2011ProPreview
Q4-2010Jan 27, 2011ProPreview
Q3-2010Oct 21, 2010ProPreview
Q2-2010Jul 15, 2010ProPreview
Q1-2010Apr 20, 2010ProPreview
Q4-2009Jan 26, 2010ProPreview
Q3-2009Oct 22, 2009ProPreview
Q2-2009Jul 16, 2009ProPreview
Q1-2009Apr 23, 2009ProPreview
Q4-2008Jan 28, 2009ProPreview
Q3-2008Oct 20, 2008ProPreview
Q2-2008Jul 17, 2008ProPreview
Q1-2008Apr 21, 2008ProPreview
Q4-2007Jan 17, 2008ProPreview